dc.contributor.author |
Tang, Shengnan |
en |
dc.contributor.author |
Wang, Aiping |
en |
dc.contributor.author |
Yan, Xiuju |
en |
dc.contributor.author |
Chu, Liuxiang |
en |
dc.contributor.author |
Yang, Xiucheng |
en |
dc.contributor.author |
Song, Yina |
en |
dc.contributor.author |
Sun, Kaoxiang |
en |
dc.contributor.author |
Yu, Xin |
en |
dc.contributor.author |
Liu, Rongxia |
en |
dc.contributor.author |
Wu, Zimei |
en |
dc.contributor.author |
Xue, Peng |
en |
dc.date.accessioned |
2020-02-18T01:10:51Z |
en |
dc.date.issued |
2019-12 |
en |
dc.identifier.citation |
Drug delivery 26(1):700-707 Dec 2019 |
en |
dc.identifier.issn |
1071-7544 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/50100 |
en |
dc.description.abstract |
Efficient delivery of brain-targeted drugs is highly important for successful therapy in Parkinson's disease (PD). This study was designed to formulate borneol and lactoferrin co-modified nanoparticles (Lf-BNPs) encapsulated dopamine as a novel drug delivery system to achieve maximum therapeutic efficacy and reduce side effects for PD. Dopamine Lf-BNPs were prepared using the double emulsion solvent evaporation method and evaluated for physicochemical and pharmaceutical properties. In vitro cytotoxicity studies indicated that treatment with dopamine Lf-BNPs has relatively low cytotoxicity in SH-SY5Y and 16HBE cells. Qualitative and quantitative cellular uptake experiments indicated that Lf modification of NPs increased cellular uptake of SH-SY5Y cells and 16HBE cells, and borneol modification can promote the cellular uptake of 16HBE. In vivo pharmacokinetic studies indicated that AUC0-12 h in the rat brain for dopamine Lf-BNPs was significantly higher (p < .05) than that of dopamine nanoparticles. Intranasal administration of dopamine Lf-BNPs effectively alleviated the 6-hydroxydopamine-induced striatum lesion in rats as indicated by the contralateral rotation behavior test and results for striatal monoamine neurotransmitter content detection. Taken together, intranasal administration of dopamine Lf-BNPs may be an effective drug delivery system for Parkinson's disease. |
en |
dc.format.medium |
Print |
en |
dc.language |
eng |
en |
dc.relation.ispartofseries |
Drug delivery |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.rights.uri |
https://creativecommons.org/licenses/by/4.0/ |
en |
dc.subject |
Brain |
en |
dc.subject |
Cells, Cultured |
en |
dc.subject |
Animals |
en |
dc.subject |
Rats |
en |
dc.subject |
Rats, Sprague-Dawley |
en |
dc.subject |
Parkinson Disease |
en |
dc.subject |
Dopamine |
en |
dc.subject |
Lactoferrin |
en |
dc.subject |
Antiparkinson Agents |
en |
dc.subject |
Drug Delivery Systems |
en |
dc.subject |
Administration, Intranasal |
en |
dc.subject |
Nanoparticles |
en |
dc.subject |
Camphanes |
en |
dc.title |
Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson's disease. |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1080/10717544.2019.1636420 |
en |
pubs.issue |
1 |
en |
pubs.begin-page |
700 |
en |
pubs.volume |
26 |
en |
dc.rights.holder |
Copyright: The authors |
en |
pubs.end-page |
707 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Journal Article |
en |
pubs.elements-id |
777182 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Pharmacy |
en |
dc.identifier.eissn |
1521-0464 |
en |
pubs.record-created-at-source-date |
2019-07-11 |
en |
pubs.dimensions-id |
31290705 |
en |